SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs informs about press release

22 Jul 2019 Evaluate

Laurus Labs has informed about the launch of the generic version of Lyrica®, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg) in US market along with its exclusive distribution partner Rising Pharmaceuticals, a Rising Pharma Holdings Inc. company. Rising recently received the final approval from the US Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA). A press release to this extent is also attached. 

\The above information is a part of company’s filings submitted to BSE.

Laurus Labs Share Price

1574.70 6.40 (0.41%)
24-Jul-2026 11:37 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1944.90
Dr. Reddys Labs. 1150.65
Cipla 1427.00
Lupin 2361.85
Zydus Lifesciences 1108.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: